{"id":31841,"date":"2025-04-15T14:35:57","date_gmt":"2025-04-15T06:35:57","guid":{"rendered":"https:\/\/flcube.com\/?p=31841"},"modified":"2025-04-15T14:35:58","modified_gmt":"2025-04-15T06:35:58","slug":"pfizer-halts-development-of-danuglipron-due-to-drug-induced-liver-injury-case","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31841","title":{"rendered":"Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case"},"content":{"rendered":"\n<p>US pharmaceutical giant Pfizer Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) has announced the termination of development for its oral GLP-1 receptor agonist danuglipron (PF-06882961) following a case of drug-induced liver injury (DILI) observed in a clinical trial participant. The hepatic abnormality resolved after discontinuation of the treatment, but Pfizer concluded that the risk-benefit profile no longer supported further development.<\/p>\n\n\n\n<p><strong>Danuglipron: Development and Clinical Profile<\/strong><br>Danuglipron was developed as an oral glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes (T2D) and obesity. Pfizer prioritized a once-daily formulation to enhance competitiveness, building on earlier twice-daily versions that demonstrated efficacy. Two dose-optimization studies (NCT06567327, NCT06568731) met pharmacokinetic objectives and identified a potentially competitive Phase III dose.<\/p>\n\n\n\n<p><strong>Clinical Trial Findings and Decision<\/strong><br>Across over 1,400 participants, liver enzyme elevations occurred at rates comparable to those seen with approved GLP-1 therapies. However, a single asymptomatic case of DILI, which resolved post-discontinuation, prompted Pfizer to reassess the drug\u2019s risk-benefit profile. After reviewing all clinical data and regulatory feedback, Pfizer decided to halt further development of danuglipron.<\/p>\n\n\n\n<p><strong>Market Impact and Future Outlook<\/strong><br>The termination of danuglipron highlights the challenges in advancing GLP-1 therapies, particularly in balancing efficacy with safety. Pfizer\u2019s decision underscores the rigorous evaluation processes required to ensure patient safety and regulatory compliance. The company will now focus its resources on other promising candidates in its pipeline.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the termination of development for its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":31843,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,863,86,309],"class_list":["post-31841","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-nyse-pfe","tag-obesity","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the termination of development for its oral GLP-1 receptor agonist danuglipron (PF-06882961) following a case of drug-induced liver injury (DILI) observed in a clinical trial participant. The hepatic abnormality resolved after discontinuation of the treatment, but Pfizer concluded that the risk-benefit profile no longer supported further development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31841\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case\" \/>\n<meta property=\"og:description\" content=\"US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the termination of development for its oral GLP-1 receptor agonist danuglipron (PF-06882961) following a case of drug-induced liver injury (DILI) observed in a clinical trial participant. The hepatic abnormality resolved after discontinuation of the treatment, but Pfizer concluded that the risk-benefit profile no longer supported further development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31841\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-15T06:35:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-15T06:35:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1510-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31841#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31841\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case\",\"datePublished\":\"2025-04-15T06:35:57+00:00\",\"dateModified\":\"2025-04-15T06:35:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31841\"},\"wordCount\":238,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31841#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1510-png.webp\",\"keywords\":[\"Clinical trial results\",\"NYSE: PFE\",\"Obesity\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31841#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31841\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31841\",\"name\":\"Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31841#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31841#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1510-png.webp\",\"datePublished\":\"2025-04-15T06:35:57+00:00\",\"dateModified\":\"2025-04-15T06:35:58+00:00\",\"description\":\"US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the termination of development for its oral GLP-1 receptor agonist danuglipron (PF-06882961) following a case of drug-induced liver injury (DILI) observed in a clinical trial participant. The hepatic abnormality resolved after discontinuation of the treatment, but Pfizer concluded that the risk-benefit profile no longer supported further development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31841#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31841\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31841#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1510-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1510-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31841#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case - Insight, China&#039;s Pharmaceutical Industry","description":"US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the termination of development for its oral GLP-1 receptor agonist danuglipron (PF-06882961) following a case of drug-induced liver injury (DILI) observed in a clinical trial participant. The hepatic abnormality resolved after discontinuation of the treatment, but Pfizer concluded that the risk-benefit profile no longer supported further development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31841","og_locale":"en_US","og_type":"article","og_title":"Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case","og_description":"US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the termination of development for its oral GLP-1 receptor agonist danuglipron (PF-06882961) following a case of drug-induced liver injury (DILI) observed in a clinical trial participant. The hepatic abnormality resolved after discontinuation of the treatment, but Pfizer concluded that the risk-benefit profile no longer supported further development.","og_url":"https:\/\/flcube.com\/?p=31841","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-15T06:35:57+00:00","article_modified_time":"2025-04-15T06:35:58+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1510-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31841#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31841"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case","datePublished":"2025-04-15T06:35:57+00:00","dateModified":"2025-04-15T06:35:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31841"},"wordCount":238,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31841#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1510-png.webp","keywords":["Clinical trial results","NYSE: PFE","Obesity","Pfizer"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31841#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31841","url":"https:\/\/flcube.com\/?p=31841","name":"Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31841#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31841#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1510-png.webp","datePublished":"2025-04-15T06:35:57+00:00","dateModified":"2025-04-15T06:35:58+00:00","description":"US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the termination of development for its oral GLP-1 receptor agonist danuglipron (PF-06882961) following a case of drug-induced liver injury (DILI) observed in a clinical trial participant. The hepatic abnormality resolved after discontinuation of the treatment, but Pfizer concluded that the risk-benefit profile no longer supported further development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31841#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31841"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31841#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1510-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1510-png.webp","width":1080,"height":608,"caption":"Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31841#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1510-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31841"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31841\/revisions"}],"predecessor-version":[{"id":31844,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31841\/revisions\/31844"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31843"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}